United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics is positioned for durable growth because its treprostinil franchise spans multiple routes—Remodulin, Tyvaso DPI, and Orenitram—giving physicians flexibility while Tyvaso DPI remains the largest revenue driver and returned to record quarterly growth of $379 million in 3Q26. The outlook is reinforced by improving PH-ILD referrals, the October 2026 Yutrepia settlement that strengthens the competitive backdrop, and a potential April 26, 2027 IPF approval that could open a much larger market of about 100,000 U.S. patients. In addition, oral ralinepag showed a 55% reduction in clinical worsening in ADVANCE OUTCOMES, the royalty buyout signals confidence, and management’s pipeline plus organ-manufacturing platform create multiple shots on goal beyond the core PAH business.

United Therapeutics is viewed negatively because its valuation depends heavily on a concentrated Tyvaso franchise, while the downside case already embeds only a 45% probability of success for Tyvaso, 90% for ralinepag, and just 10% for the platform. That profile leaves limited cushion if clinical execution falters, regulatory hurdles intensify, or intellectual property protection weakens, any of which could undermine sustained efficacy and delay commercialization. With competition and long-term pricing pressure also cited as risks, the company’s revenue base remains vulnerable despite its leadership in PAH and its reliance on U.S. sales.